Skip to main content
SpringerLink
Log in

Glomerular disease

The search goes on: suPAR is not the elusive FSGS factor

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

New research indicates that intact soluble urokinase plasminogen activator receptor (suPAR) does not induce albuminuria in mice. These data corroborate the most recent clinical findings, showing that intact suPAR is not the plasma permeability factor responsible for recurrence of focal segmental glomerulosclerosis after renal transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Deegens, J. K. & Wetzels, J. F. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int. 80, 798–801 (2011).

    Article  CAS  Google Scholar 

  2. Maas, R. J., Deegens, J. K. & Wetzels, J. F. Serum suPAR in patients with FSGS: trash or treasure? Paediatr. Nephrol. 28, 1041–1048 (2013).

    Article  Google Scholar 

  3. Cathelin, D. et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2013040425.

  4. Rea, R., Smith, C., Sandhu, K., Kwan, J. & Tomson, C. Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 16, 416–417 (2001).

    Article  CAS  Google Scholar 

  5. McCarthy, E. T., Sharma, M. & Savin, V. J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 5, 2115–2121 (2010).

    Article  PubMed  Google Scholar 

  6. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952–960 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Wei, C. et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55–63 (2008).

    Article  CAS  PubMed  Google Scholar 

  8. Schlondorff, D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int. 85, 499–501 (2014).

    Article  CAS  Google Scholar 

  9. Meijers, B. et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 85, 636–640 (2014).

    Article  CAS  Google Scholar 

  10. Bock, M. E., Price, H. E., Gallon, L. & Langman, C. B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-centre report. Clin. J. Am.Soc. Nephrol. 8, 1304–1311 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Radboud University Medical Centre, PO Box 9101, Nijmegen, 6500, HB, Netherlands

    Jeroen K. Deegens & Jack F. Wetzels

Authors
  1. Jeroen K. Deegens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jack F. Wetzels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack F. Wetzels.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deegens, J., Wetzels, J. The search goes on: suPAR is not the elusive FSGS factor. Nat Rev Nephrol 10, 431–432 (2014). https://doi.org/10.1038/nrneph.2014.113

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2014.113

  • Springer Nature Limited

This article is cited by

Search

Navigation